SCHEMBL946852

SCHEMBL946852

CNC=CN(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940990 1.00
SCHEMBL689008 1.00
SCHEMBL23097874 0.76
SCHEMBL22677261 0.76
SCHEMBL29335541 0.76
SCHEMBL25955534 0.76
SCHEMBL18630353 0.74
SCHEMBL22931432 0.72
SCHEMBL21965060 0.72
SCHEMBL16084910 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4186888-A1 COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ModernaTX, Inc. (US) 2023-05-31 EP disclosed
US-20220409536-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2022-12-29 US disclosed
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 EP disclosed
US-20210283264-A1 Polymeric Prodrugs with a Self-Immolative Linker ASCENDIS PHARMA GMBH (DE) 2021-09-16 US disclosed
US-20210154148-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2021-05-27 US disclosed
EP-3759091-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY Thomas Helledays stiftelse för medicinsk forskning (SE) 2021-01-06 EP disclosed
US-10857105-B2 Compounds and compositions for intracellular delivery of therapeutic agents MordernaTX, Inc. (US) 2020-12-08 US disclosed
US-20190314292-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2019-10-17 US disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 US disclosed
EP-1732607-B1 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER ASCENDIS PHARMA GMBH (DE) 2019-05-15 EP disclosed
EP-1625855-A1 Polymeric prodrug with a self-immolative linker Complex Biosystems GmbH (DE) 2006-02-15 EP disclosed
WO-2005099768-A2 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER COMPLEX BIOSYSTEMS GMBH (DE) 2005-10-27 WO disclosed
EP-1581492-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Suven Life Sciences Limited (IN) 2005-10-05 EP disclosed
WO-2004108671-A1 SUBSTITUTED INDOLES WITH SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2004-12-16 WO disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed
WO-2004048330-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
US-4242516-A Fluorinated amphoteric surfactants CIBA-GEIGY CORPORATION (US) 1980-12-30 US disclosed
US-4161590-A Fluorinated amphoteric and cationic surfactants CIBA-GEIGY CORPORATION (US) 1979-07-17 US disclosed
US-4161602-A Fluorinated amphoteric and cationic surfactants containing a pyridinium moiety CIBA-GEIGY CORPORATION (US) 1979-07-17 US disclosed
US-4069244-A THIO-CARBOXYLIC ACIDS CIBA-GEIGY CORPORATION (US) 1978-01-17 US disclosed